Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug ...

Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
Science Daily

SARS-CoV-2 'steals' our proteins to protect itself from the immune system

Researchers have discovered that SARS-CoV-2 hijacks three important host proteins that dampen the activity of the complement system, a key component of early antiviral immunity. This significantly ...
The American Journal of Managed Care

iAMD Progression Linked to Dysregulation of Complement Pathways

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...
Morningstar

Complement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
The Harvard Crimson

HMS Researchers Discover Key Protein in Activating Autoimmune Responses

Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and autoimmune conditions when it turns against the body. The protein, Granzyme K, ...